Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals

Core Viewpoint - The strategic agreement between CC Pharma and Smartway Pharmaceuticals aims to enhance the distribution of pharmaceutical products in the UK, marking a significant step in Tilray's European medical expansion strategy [1][2][4]. Group 1: Agreement Details - CC Pharma and Smartway will collaborate to expand parallel import and specialist pharmaceutical supply in the UK, utilizing Smartway's national distribution infrastructure and CC Pharma's European procurement capabilities [2][4]. - The UK pharmaceutical market is valued at nearly £1 billion, positioning Tilray and CC Pharma to improve access and supply reliability through established healthcare channels [3][4]. Group 2: Strategic Importance - The UK is identified as a priority market within Tilray's international medical strategy, with the agreement expected to enhance access to medicinal products and support long-term growth in Europe [4][5]. - The partnership is built on a longstanding relationship since 2009, focusing on cross-border pharmaceutical collaboration and supply chain execution [4][5]. Group 3: Leadership Insights - Rajnish Ohri, President of International at Tilray Brands, emphasized the agreement's role in broadening access to medicinal products and embedding Tilray into the UK health system [4]. - Mathias Bossen, Managing Director of CC Pharma, highlighted the importance of leveraging Smartway's national network to enhance supply reliability for pharmacy and hospital partners [5].